Novavax said it will look into developing a combined influenza/COVID-19 vaccine for post-pandemic use that would unite two of its vaccine candidates.

The company is currently seeking FDA approval of the influenza vaccine, NanoFlu, supported by positive results from a phase 3 trial. The Maryland-based company is also developing a coronavirus vaccine, NVX-CoV2373.

A late-stage trial of NVX-CoV2373 is expected to get under way in late November and produce efficacy data around March 2021. The company has created a new team that will explore a combined product.